VISION

The vision is to build a world-leading immuno-oncology company that brings safe and effective vaccines to the patients. We will reach that by executing on different activities.

TRACTION

Very strong preclinical data: Remove tumors and make animals immune to new cancers – and also utilizes the gold-standard for vaccine delivery technology into the cancer immunotherapy field.

OUR WAY

Treating cancer by targeting tumor viruses within our genome since current treatment methods are not only unsatisfactory but also extremely harsh on the patient and his/her life quality.

THE ROAD FORWARD

Ambitious milestones are to be achieved in the coming 12 to 18 months – preparing the company for future VC funding, GMP and clinical trials in collaboration with leading clinical experts. 

NEWS

GET IN CONTACT

Peter

Peter J. Holst
CSO

  

Nicolaj

Nicolaj H. Nielsen
CFO

  

QUESTIONS

  RESEARCH IN YOUR INBOX

– Always be updated on our research. 

WordPress Theme built by Shufflehound.